In human papillary thyroid cancer (PTC) cells, TRIM44 knockdown inhibited the proliferation, migration and invasion of PTC cells by inactivating the Wnt/β-catenin signaling pathway; and LiCl, an activator of the Wnt/β-catenin pathway, rescued the anticancer effect of TRIM44 knockdown in PTC cells (Figure 5) (Zhou et al., 2017). Here, TRIM44 is linked to thyroid gland papillary carcinoma.